BridgeMD
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder
EU CTIS ID: 2025-524163-21-00
What this study is testing
To investigate the effect of Semaglutide (Wegovy®) 2.4 mg S.C., compared with placebo, on total cannabis consumption in adults with Cannabis Use Disorder
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Informed oral and written consent.
- Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.
- Currently seeking to cut down or stop cannabis use.
- Positive urine test for cannabinoids.
- Body mass index (BMI) ≥ 23 kg/m².
- Age 18–70 years.
You likely can't join if
- Currently meeting non-cannabis/tobacco substance use disorder (ICD-10 or DSM-5).
- History of medullary thyroid carcinoma (MTC) and/or family history of MTC and/or Multiple Endocrine Neoplasia type 2 (MEN 2).
- Heart disease defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, and/or myocardial infarction within the past 12 months
- Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >110 mmHg).
- Receipt of experimental medication within the past 30 days.
- Use of weight-loss medication within the past 3 months.
See the full eligibility criteria
- Informed oral and written consent.
- Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.
- Currently seeking to cut down or stop cannabis use.
- Positive urine test for cannabinoids.
- Body mass index (BMI) ≥ 23 kg/m².
- Age 18–70 years.
- Recent frequent cannabis use, defined as use on ≥16 days out of the past 28 days.
- Cannabis use (smoked, vaped, edibles) equivalent to THC doses of ≥14 grams in the past 28 days before baseline.
- Ability to comply with study procedures and follow-up.
- Currently meeting non-cannabis/tobacco substance use disorder (ICD-10 or DSM-5).
- History of medullary thyroid carcinoma (MTC) and/or family history of MTC and/or Multiple Endocrine Neoplasia type 2 (MEN 2).
- Heart disease defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, and/or myocardial infarction within the past 12 months
- Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >110 mmHg).
- Receipt of experimental medication within the past 30 days.
- Use of weight-loss medication within the past 3 months.
- Hypersensitivity to the active substance or any of the excipients.
- For patients undergoing brain scanning only: Contraindications to MRI scanning (magnetic implants, pacemaker, claustrophobia, etc.).
- Inability to speak and/or understand Danish
- Other conditions: Any other condition that, in the investigator's opinion, may interfere with participation in the trial.
- Current or past diagnosis of severe psychiatric illness, defined as schizophrenia, bipolar disorder, or other psychoses, within the past five years.
- Suicide attempt or suicidal behavior within the past five years.
- Severe neurological disorders, including previous severe traumatic brain injury, stroke, or intracranial hemorrhage.
- Type 1 diabetes and type 2 diabetes.
- Pregnant or potentially pregnant women: Women of childbearing potential (WOCBP) who are pregnant, breastfeeding, planning to become pregnant within the next eight months (including 20 weeks of treatment plus two months after discontinuation of semaglutide), or not using effective contraception throughout the study period. Effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, implant, injection), intrauterine device/system (IUD/IUS), bilateral tubal occlusion, partner with vasectomy, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level >3 U/L at inclusion will also be excluded.
- Impaired liver function (liver transaminases >3 times the upper reference limit)
- Impaired renal function (eGFR <50 ml/min and/or plasma creatinine >150 µmol/L).
- Impaired pancreatic function (past or current acute or chronic pancreatitis and/or amylase >2 times the upper limit).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.